Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
NCT00451763Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Jan 2006
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3 trial of bevacizumab in idiopathic macular telangiectasia (MacTel), sponsored by Universidade de São Paulo. Primary endpoints: Visual Acuity, Optical Coherence Tomography and 1 more. Started Jan 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
idiopathic macular telangiectasia (MacTel)
Beyond the preview
Go deeper on NCT00451763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451763.